Magnesium Supplementation for Primary Prevention of Heart Failure in Obesity

Completed · Not applicable

Conditions studied: Obesity

In brief

The objective of this study is to investigate whether nutritional supplementation with magnesium can improve cardiovascular structure and function in participants with obesity - with a long-term goal of preventing clinical heart failure. Specifically, in a randomized open-label pilot study, we will assess whether dietary Magnesium (Mg) supplementation (versus no supplementation) for 24 weeks in obese patients will improve left ventricular (LV) mass.

Key facts

Study ID

NCT02966912

Run by

Providence VA Medical Center

People needed

40

Starts

2016-11-01

Expected to finish

2019-09-01

Last updated by the study team

2023-02-24

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body mass index greater than 30 kg/m2

You may not qualify if…

• History of hospitalization for heart failure (systolic or diastolic);
• Unstable angina or prior myocardial infarction;
• LV ejection fraction <50% on imaging study;
• Valvular heart disease (stenosis or insufficiency) greater than moderate degree;
• Renal dysfunction, serum creatinine >2.5 mg/dL or estimated creatinine clearance <30 mL/min/1.73 m2 (30),
• Pregnant women or actively breastfeeding women
• History of drug supplementation within the last 6 months in which more than 50 miliequivalents per day of supplemental magnesium is contained

Where it is running

• Providence VA Medical Center — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.